BRPI0412424A - composto, composição farmacêutica, método para tratar doenças dermatológicas ou cancerosas em um mamìfero, composição, e, método para tratar doenças relacionadas com a pele ou cancerosas - Google Patents

composto, composição farmacêutica, método para tratar doenças dermatológicas ou cancerosas em um mamìfero, composição, e, método para tratar doenças relacionadas com a pele ou cancerosas

Info

Publication number
BRPI0412424A
BRPI0412424A BRPI0412424-3A BRPI0412424A BRPI0412424A BR PI0412424 A BRPI0412424 A BR PI0412424A BR PI0412424 A BRPI0412424 A BR PI0412424A BR PI0412424 A BRPI0412424 A BR PI0412424A
Authority
BR
Brazil
Prior art keywords
composition
cancerous diseases
treating
pharmaceutical composition
mammal
Prior art date
Application number
BRPI0412424-3A
Other languages
English (en)
Inventor
Vanessa Smith
Anthony Nigro
Mark Mulvihill
Cara Cesario
Patricia Anne Beck
Arlindo L Castelhano
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of BRPI0412424A publication Critical patent/BRPI0412424A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAR DOENçAS DERMATOLóGICAS OU CANCEROSAS EM UM MAMìFERO, COMPOSIçãO, E, MéTODO PARA TRATAR DOENçAS RELACIONADAS COM A PELE OU CANCEROSAS". Compostos da fórmula (I); e sais destes farmaceuticamente aceitáveis, em que n1, n2, n3, n4, G¬ 1¬, Q¬ 1¬, Z, R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4a¬, R¬ 4b¬ , R¬ 5a¬ e R¬ 5b¬ são aqui definidos, inibem a enzima P450RAI citocrómica e são úteis para o tratamento e/ou prevenção de várias doenças e condições que respondem ao tratamento pelos retinóides e pelo ácido retinóico que ocorre naturalmente.
BRPI0412424-3A 2003-07-10 2004-07-12 composto, composição farmacêutica, método para tratar doenças dermatológicas ou cancerosas em um mamìfero, composição, e, método para tratar doenças relacionadas com a pele ou cancerosas BRPI0412424A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
PCT/US2004/022282 WO2005007631A1 (en) 2003-07-10 2004-07-12 Naphthylene derivatives as cytochrome p450 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0412424A true BRPI0412424A (pt) 2006-09-05

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412424-3A BRPI0412424A (pt) 2003-07-10 2004-07-12 composto, composição farmacêutica, método para tratar doenças dermatológicas ou cancerosas em um mamìfero, composição, e, método para tratar doenças relacionadas com a pele ou cancerosas

Country Status (15)

Country Link
EP (1) EP1654236A1 (pt)
JP (1) JP4832295B2 (pt)
KR (1) KR20060052799A (pt)
CN (1) CN1819996B (pt)
AU (1) AU2004257257B2 (pt)
BR (1) BRPI0412424A (pt)
CA (1) CA2532078A1 (pt)
IL (1) IL172812A0 (pt)
IS (1) IS8223A (pt)
MX (1) MXPA06000401A (pt)
NO (1) NO20060114L (pt)
RU (1) RU2363696C2 (pt)
SG (1) SG144941A1 (pt)
UA (1) UA87822C2 (pt)
WO (1) WO2005007631A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696899A1 (en) 2003-12-17 2006-09-06 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
JP6088425B2 (ja) 2010-06-01 2017-03-01 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
EP2638021B1 (en) * 2010-11-13 2018-09-26 Innocrin Pharmaceuticals, Inc. 1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer
EA201390876A1 (ru) * 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
HUE055262T2 (hu) 2014-08-11 2021-11-29 Angion Biomedica Corp Citokróm P450 inhibitorok és ezek alkalmazásai
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
EP3568392B1 (de) 2017-01-10 2021-02-24 Bayer Aktiengesellschaft Imidazol-derivate als schädlingsbekämpfungsmittel
KR20230020566A (ko) 2017-01-10 2023-02-10 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (pt) * 1960-05-04
NL131915C (pt) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
AU5285593A (en) * 1992-10-21 1994-05-09 Sankyo Company Limited Azole compound
DE69924717T2 (de) * 1998-04-23 2006-03-09 Takeda Pharmaceutical Co. Ltd. Naphthalene derivate ,ihre herstellung und verwendung
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類

Also Published As

Publication number Publication date
CA2532078A1 (en) 2005-01-27
AU2004257257A1 (en) 2005-01-27
JP4832295B2 (ja) 2011-12-07
KR20060052799A (ko) 2006-05-19
NO20060114L (no) 2006-02-09
UA87822C2 (ru) 2009-08-25
CN1819996B (zh) 2010-10-27
EP1654236A1 (en) 2006-05-10
RU2363696C2 (ru) 2009-08-10
CN1819996A (zh) 2006-08-16
MXPA06000401A (es) 2006-03-17
WO2005007631A1 (en) 2005-01-27
IL172812A0 (en) 2006-06-11
IS8223A (is) 2006-01-10
AU2004257257B2 (en) 2011-05-12
SG144941A1 (en) 2008-08-28
RU2006103996A (ru) 2006-07-10
JP2007523866A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
BRPI0412424A (pt) composto, composição farmacêutica, método para tratar doenças dermatológicas ou cancerosas em um mamìfero, composição, e, método para tratar doenças relacionadas com a pele ou cancerosas
BRPI0512253A (pt) composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BRPI0515500A (pt) derivados piridazina para inibição de estearoil-coa-desaturase
UA81629C2 (ru) Применение композиции и способ лечения инфекционных заболеваний крупного рогатого скота и свиней
BRPI0408476A (pt) métodos para melhorar a qualidade da pele
EA200901555A1 (ru) Композиция местного применения по уходу за кожей и способ лечения
BR0309890A (pt) Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação
BRPI0514295A (pt) 1, 5-difenilpirazóis
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
ATE341550T1 (de) Quinolinyl-pyrrolopyrazole
BR0313630A (pt) Composição para aplicação tópica, sistema para o tratamento de caspa, métodos para o tratamento e/ou prevenção da caspa e da coceira do couro cabeludo e usos de uma combinação sinérgica
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0114344B8 (pt) composto retinóide, seu uso, sua composição farmacêutica e seu processo de preparação
BR0208052A (pt) Composição que inibe matriz metaloproteinases para o tratamento de doenças neoplásicas
DE69932939D1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
BR0314261A (pt) Compostos, processo de preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de um composto, método para tratamento e/ou profilaxia de enfermidades e utilização e/ou método de tratamento
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.